drugset
drugset / Trial / NCT05237713

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

NCT05237713 ↗

Phase 2 Terminated 10 enrolled University of Leipzig Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.

Timeline

Start
2022-04-26
Primary completion
2024-02-29
Completion
2024-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 200 mg Subcutaneous

Indications

anemia myelodysplastic syndrome